ArticleCurrent infectious disease reports2015
Update on Neurological Manifestations of HTLV-1 Infection.
Article in Current infectious disease reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Case of concurrent ALS and human T-cell leukaemia virus type 1-associated myositis.BMJ case reports · 2026Article
- Morbidity and Mortality Among People Living With HTLV-1: A 30-Year Retrospective Analysis in a Brazilian Cohort.Journal of medical virology · 2026Article
- Chronic Neuroplasticity Changes Following Neurotropic Viral Infection: Mechanisms and Implications.Cellular and molecular neurobiology · 2025Review
- Article
- HTLV-1-Associated Myelopathy (HAM) Incidence in Asymptomatic Carriers and Intermediate Syndrome (IS) Patients.Pathogens (Basel, Switzerland) · 2024Article
- Imaging Spectrum of HTLV-1-Related Neurologic Disease: A Pooled Series and Review.Neurology. Clinical practice · 2023Review
- Comparison of Static Balance Control in Infected Htlv-1 Subjects with Different Tsp/Ham Diagnosis.Viruses · 2022Article
- Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- The role of IFN-γ production during retroviral infections: an important cytokine involved in chronic inflammation and pathogenesis.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Review
- Association between Cognitive Function and Depression with Human T-Cell Lymphotropic Virus 1 Seropositivity and Serointensity in UK Adults.Pathogens (Basel, Switzerland) · 2021Article
- Brazilian Protocol for Sexually Transmitted Infections 2020: human T-cell lymphotropic virus (HTLV) infection.Revista da Sociedade Brasileira de Medicina Tropical · 2021Article
- HTLV in South America: Origins of a silent ancient human infection.Virus evolution · 2020Article
- The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil.Retrovirology · 2020Review
- Influence of Immunogenetic Biomarkers in the Clinical Outcome of HTLV-1 Infected Persons.Viruses · 2019Review
- Infectious agents and amyotrophic lateral sclerosis: another piece of the puzzle of motor neuron degeneration.Journal of neurology · 2019Review
- Mother-to-Child HTLV-1 Transmission: Unmet Research Needs.Frontiers in microbiology · 2019Review
- Sensory neuronopathy heralding human T cell lymphotropic virus type I myelopathy.Journal of neurovirology · 2018Article
- Enteroviral Infection: The Forgotten Link to Amyotrophic Lateral Sclerosis?Frontiers in molecular neuroscience · 2018Review
- Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon.Revista do Instituto de Medicina Tropical de Sao Paulo · 2017Article
- Prevalence and risk factors for Human T-Lymphotropic Virus Type 1 (HTLV-1) among maintenance hemodialysis patients.BMC nephrology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human T cell lymphotropic virus type 1 (HTLV-1) is a retrovirus that infects 10-20 million persons around the world. Initially associated with the hematological malignancy adult T cell leukemia/lymphoma (ATLL), HTLV-1 is also the cause of a chronic progressive myelopathy named "HTLV-1-associated myelopathy/tropical spastic paraparesis" (HAM/TSP). HAM/TSP arises as the tip of the iceberg of an assortment of neurological syndromes triggered by the virus such as inflammatory myopathies, polyneuropathies, amyotrophic lateral sclerosis (ALS)-like syndromes, dysautonomia, and cognitive impairment. HAM/TSP typifies a chronic progressive spastic paraparesis with neurogenic bladder and minimal sensory signs. The neuropathology of HAM/TSP is concentrated in the thoracic spinal cord and is typically biphasic. Initially, there is a perivascular lymphocytic cuffing and mild parenchymal mononuclear infiltrates. Subsequently, this is replaced by gliosis and scarring. The neuropathogenesis of HTLV-1 is still partially understood. At present, the therapy of HAM/TSP remains basically symptomatic.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.